论文部分内容阅读
目的探讨CK19mRNA、CEAmRNA能否作为判断肺癌血源性微转移的参考指标。方法取67例肺癌患者及37例健康体检者外周血,应用逆转录聚合酶链反应RT-PCR法检测上述两个指标的表达。结果肺癌组外周血中CK19mRNA阳性率(57.6%)及CEAmRNA阳性率(52.2%)均显著高于健康对照组的2.7%和5.4%(均P<0.01),两个指标联合检测能将对肺癌微转移诊断的灵敏度提高至76.1%;CK19mRNA的表达与临床分期相关(P<0.01),CEAmRNA的表达与组织类型相关(P<0.05)。结论CK19mRNA和CEAmRNA可作为判断肺癌血源性微转移的参考指标,两者联检可提高诊断价值。
Objective To investigate whether CK19mRNA and CEAmRNA can be used as reference markers for determining micrometastasis of lung cancer. Methods The peripheral blood of 67 patients with lung cancer and 37 healthy controls were collected. The expression of these two indexes was detected by RT-PCR. Results The positive rates of CK19 mRNA (57.6%) and CEA mRNA (52.2%) in peripheral blood of patients with lung cancer were significantly higher than those of healthy controls by 2.7% and 5.4% (all P <0.01) The sensitivity of micrometastasis diagnosis increased to 76.1%. The expression of CK19 mRNA was correlated with clinical stage (P <0.01). The expression of CEA mRNA was correlated with tissue type (P <0.05). Conclusions CK19mRNA and CEAmRNA can be used as reference markers for judging the blood-borne micrometastasis in lung cancer. The combination of CK19mRNA and CEAmRNA can improve the diagnostic value.